H
Horacio Mingrone
Publications - 3
Citations - 533
Horacio Mingrone is an academic researcher. The author has contributed to research in topics: Public health & Viral load. The author has an hindex of 3, co-authored 3 publications receiving 480 citations.
Papers
More filters
Journal ArticleDOI
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Pedro Cahn,Anton Pozniak,Horacio Mingrone,Andrey Shuldyakov,Carlos Brites,Jaime Andrade-Villanueva,Gary Richmond,Carlos Beltran Buendia,Jan Fourie,Moti Ramgopal,Debbie Hagins,Franco Felizarta,José Valdez Madruga,Tania Reuter,Tamara Newman,Catherine B. Small,John Lombaard,Beatriz Grinsztejn,David Dorey,Mark R. Underwood,Sandy Griffith,Sherene Min +21 more
TL;DR: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group.
Journal ArticleDOI
Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters
M. Eugenia Socías,Omar Sued,Natalia Laufer,María Esther Lázaro,Horacio Mingrone,Daniel Pryluka,Carlos Remondegui,María Inés Figueroa,Carina Cesar,Ana Gun,Gabriela Turk,María Belén Bouzas,Ravi Kavasery,Alejandro J. Krolewiecki,Héctor Pérez,Horacio Salomón,Pedro Cahn +16 more
TL;DR: In Argentina, PHI is associated with significant morbidity and HAART should be considered in PHI patients with ARS and high baseline VL to prevent disease progression, according to a multicentre registry of patients diagnosed between 1997 and 2008.
Journal ArticleDOI
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
Roberto Zajdenverg,Thomas Podsadecki,Sharlaa Badal-Faesen,Jaime Andrade-Villanueva,Joseph Gathe,Horacio Mingrone,Linda M Fredrick,Isabelle A. Gaultier,W Chris Woodward,Bernstein Barry M +9 more
TL;DR: LPV/ r dosed QD resulted in increased treatment adherence and was as efficacious as BID LPV/r while providing similar safety, tolerability, and limited resistance evolution.